To rescue cognition in schizophrenia with valaciclovir: a focus on hippocampal inflammation

To rescue cognition in schizophrenia with valaciclovir: a focus on hippocampal inflammation - To rescue cognition with valaciclovir

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON38222

Enrollment

Registered

2009-04-16

Start date

2011-04-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychiatric disorder schizophrenia

Interventions

Of the 24 included patients, 12 patients will receive 8 g (4x2 g per day) of valaciclovir daily for a period of 7 consecutive 24-h periods and 12 patients will receive 8 g (4x2 g per day) of placebo

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Age above 18 -Written informed consent for participation -Diagnosis: schizophrenia, all subtypes -Psychosis

Exclusion criteria

Exclusion criteria: -Pregnancy, or presumption of pregnancy -The use of benzodiazepines -The use of NSAID or paracetamol in week before the PET scans and during the treatment of valaciclovir -Use of somatic medication which may affect the immune system -Use of any investigational drug -Current or recent (

Design outcomes

Primary

Measure	Time frame
The main study parameters are the pre-and post-treatment [11C]-PK11195 binding potential in the hippocampus.	—

Secondary

Measure	Time frame
Secondary study parameters are the pre- and post-treatment performance on the PANSS, the attention, memory and IQ test, the antibodies against common viruses and the pre- and post-treatment [11C]-PK11195 binding potential in other brain areas than the hippocampus.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)